C3-mediated Extravascular Hemolysis In PNH On Eculizumab
Có thể bạn quan tâm
Abstract
The introduction of eculizumab, a human monoclonal antibody against the C5 component of complement, has changed radically the management of paroxysmal nocturnal hemoglobinuria (PNH). The blockade of the terminal complement pathway by eculizumab abrogates intravascular hemolysis, reduces the transfusion requirement and the risk of thrombosis in most of hemolytic PNH patients. However, in almost all PNH patients on eculizumab arises a fraction of PNH red cells that bind fragments of C3 and become a potential target of phagocytosis by macrophages. Eventually, this phagocytosis results in a variable degree of extravascular hemolysis that may reduce clinical benefits of eculizumab and, in fact, about one-fourth of patients remain transfusion-dependent. The treatment of the few PNH patients in which this de novo extravascular hemolysis become clinically relevant is still unsatisfactory. Nevertheless, the investigations of the mechanisms responsible of the extravascular hemolysis on eculizumab have resulted in the development of novel strategies for complement blockade that could overcome this condition.
Keywords: C3; C5; Paroxysmal nocturnal hemoglobinuria; complement inhibition; extravascular hemolysis; intravascular hemolysis.
Copyright © 2018 Elsevier Inc. All rights reserved.
PubMed Disclaimer
Publication types
- Review Actions
- Search in PubMed
- Search in MeSH
- Add to Search
MeSH terms
- Antibodies, Monoclonal, Humanized / pharmacology Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Antibodies, Monoclonal, Humanized / therapeutic use* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C3 / metabolism* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Hemoglobinuria, Paroxysmal / drug therapy* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Hemolysis Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Humans Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Substances
- Antibodies, Monoclonal, Humanized Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C3 Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- eculizumab Actions
- Search in PubMed
- Search in MeSH
- Add to Search
LinkOut - more resources
Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal
Từ khóa » C3 Pnh
-
Trường THPT Phan Ngọc Hiển
-
C3 Inhibitor Prevails In Trial Of Rare Hemoglobinuria | MedPage Today
-
Targeting Complement C3 Improves Outcomes In Paroxysmal ...
-
C3 Inhibitor Shows Potential In PNH And AIHA - MDedge
-
Effect Of C3 Inhibitors On Hemolysis And C3 Fragment Deposition Of ...
-
In Vivo C3 Binding On Red Cells Of PNH Patients On Eculizumab. A...
-
C3-mediated Extravascular Hemolysis In PNH On Eculizumab
-
Pegcetacoplan ‐ A Novel C3 Inhibitor For Paroxysmal Nocturnal ...
-
Eculizumab Treatment: Stochastic Occurrence Of C3 Binding To ...
-
Apellis' PNH Victory Lap: Newly FDA-approved Empaveli Helped ...
-
Paroxysmal Nocturnal Haemoglobinuria (PNH) - Sobi
-
First Approval Of A Complement C3 Inhibitor Opens Up Autoimmune ...
-
Apellis Announces U.S. Food And Drug Administration (FDA ...